The Pan-PIM Kinase Inhibitor LGH447 Shows Activity In PIM2-Dependent Multiple Myeloma and In AML Models

髓系白血病 白血病 硼替佐米 细胞生长
作者
John L. Langowski,Jocelyn Holash,Matthew Burger,Richard Zang,Tatiana Zavorotinskaya,Christie Fanton,Abdel Saci,Joseph D. Growney,K. Gary Vanasse
出处
期刊:Blood [Elsevier BV]
卷期号:122 (21): 1666-1666 被引量:9
标识
DOI:10.1182/blood.v122.21.1666.1666
摘要

Background PIM1, PIM2, and PIM3 are a closely related family of constitutively active serine/threonine kinases. PIM kinases were first identified as common integration sites in MMLV-induced murine T-cell lymphomas, with these viral insertions resulting in transcriptional activation and expression of the kinase. Similar unbiased insertional mutagenesis screens were used to demonstrate that the three kinases could substitute for each other in this oncogenic process, indicating that inhibition of all three PIM kinases may be necessary to achieve a therapeutic benefit. In human cancers, increased expression and activity of PIM kinases has been detected in many hematopoietic malignancies and solid tumors (prostate, lung, liver) and it is thought that this contributes to cancer cell survival and proliferation in these malignancies. Methods & Results We have developed a potent and specific pan-PIM inhibitor, LGH447, and shown that it is active in PIM2-dependent Multiple Myeloma (MM) cell lines by inhibiting proliferation, mTOR-C1 signaling and phosphorylation of BAD. In addition, LGH447 inhibited proliferation of several AML cell lines. Furthermore, we demonstrated that LGH447 inhibits tumor growth in several mouse subcutaneous xenograft models of MM and AML, where modulation of the pharmacodynamic marker phospho-S6 Ribosomal Protein was used to predict efficacy. We have also determined that LGH447 significantly reduced the bone tumor burden in a disseminated orthotopic human xenograft model of MM. Finally, we have demonstrated increased activity of LGH447 in combination with the PI3K inhibitor BYL719 in a MM model and with Cytarabine in an AML model. Summary Our Results have supported the clinical development of LGH447, a Pan-PIM inhibitor, in relapsed, refractory MM, and further suggest that it may be effective in the treatment of AML and other hematological malignancies, either as a single agent or in combination with other select therapeutic agents. Disclosures: Garcia: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Langowski: Novartis Institutes for Biomedical Research: Employment. Holash: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Burger: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Zang: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Zavorotinskaya: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Fanton: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Saci: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Growney: Novartis Institutes for Biomedical Research: Employment, Equity Ownership. Vanasse: Novartis Pharmaceuticals Corporation: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被tang采纳,获得10
刚刚
wyy发布了新的文献求助10
1秒前
1秒前
nana完成签到,获得积分10
2秒前
隐形曼青的应助被BBzc采纳,获得10
2秒前
2秒前
鹿立轩发布了新的文献求助10
3秒前
3秒前
Yoyo发布了新的文献求助10
3秒前
4秒前
LLJ完成签到,获得积分10
4秒前
4秒前
传奇3的应助被兵临城下采纳,获得10
5秒前
林xxxx发布了新的文献求助10
5秒前
吴军霄发布了新的文献求助10
5秒前
jj发布了新的文献求助10
7秒前
7秒前
健忘冰珍完成签到,获得积分10
8秒前
9秒前
10秒前
小高完成签到 ,获得积分10
10秒前
zhfliang发布了新的文献求助10
10秒前
Ava的应助被大大怪采纳,获得10
12秒前
然然发布了新的文献求助10
12秒前
12秒前
u110完成签到,获得积分10
13秒前
13秒前
吴军霄完成签到,获得积分10
13秒前
13秒前
13秒前
嘀嘀嘀发布了新的文献求助10
15秒前
壹肆伍完成签到,获得积分10
16秒前
健忘冰珍发布了新的文献求助10
16秒前
芜湖发布了新的文献求助10
16秒前
鹿立轩完成签到,获得积分10
17秒前
阿biuu发布了新的文献求助10
17秒前
18秒前
兵临城下发布了新的文献求助10
18秒前
开心青柏完成签到 ,获得积分10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814